Display options
Cite
Stiborová M, Poljaková J, Martínková E, et al. Ellipticine cytotoxicity to cancer cell lines - a comparative study. Interdiscip Toxicol. 2011;4(2):98-105doi: 10.2478/v10102-011-0017-7.
Stiborová, M., Poljaková, J., Martínková, E., Bořek-Dohalská, L., Eckschlager, T., Kizek, R., & Frei, E. (2011). Ellipticine cytotoxicity to cancer cell lines - a comparative study. Interdisciplinary toxicology, 4(2), 98-105. https://doi.org/10.2478/v10102-011-0017-7
Stiborová, Marie, et al. "Ellipticine cytotoxicity to cancer cell lines - a comparative study." Interdisciplinary toxicology vol. 4,2 (2011): 98-105. doi: https://doi.org/10.2478/v10102-011-0017-7
Stiborová M, Poljaková J, Martínková E, Bořek-Dohalská L, Eckschlager T, Kizek R, Frei E. Ellipticine cytotoxicity to cancer cell lines - a comparative study. Interdiscip Toxicol. 2011 Jun;4(2):98-105. doi: 10.2478/v10102-011-0017-7. PMID: 21753906; PMCID: PMC3131681.
Copy Download .nbib Format: NLM
Share it on

Interdiscip Toxicol. 2011 Jun;4(2):98-105. doi: 10.2478/v10102-011-0017-7.

Ellipticine cytotoxicity to cancer cell lines - a comparative study.

Interdisciplinary toxicology

Marie Stiborová, Jitka Poljaková, Eva Martínková, Lucie Bořek-Dohalská, Tomáš Eckschlager, Rene Kizek, Eva Frei

Affiliations

  1. Department of Biochemistry, Faculty of Science, Charles University, Prague, Czech Republic.

PMID: 21753906 PMCID: PMC3131681 DOI: 10.2478/v10102-011-0017-7

Abstract

Ellipticine is a potent antineoplastic agent exhibiting multiple mechanisms of action. This anticancer agent should be considered a pro-drug, whose pharmacological efficiency and/or genotoxic side effects are dependent on its cytochrome P450 (CYP)- and/or peroxidase-mediated activation to species forming covalent DNA adducts. Ellipticine can also act as an inhibitor or inducer of biotransformation enzymes, thereby modulating its own metabolism leading to its genotoxic and pharmacological effects. Here, a comparison of the toxicity of ellipticine to human breast adenocarcinoma MCF-7 cells, leukemia HL-60 and CCRF-CEM cells, neuroblastoma IMR-32, UKF-NB-3 and UKF-NB-4 cells and U87MG glioblastoma cells and mechanisms of its action to these cells were evaluated. Treatment of all cells tested with ellipticine resulted in inhibition of cell growth and proliferation. This effect was associated with formation of two covalent ellipticine-derived DNA adducts, identical to those formed by 13-hydroxy- and 12-hydroxyellipticine, the ellipticine metabolites generated by CYP and peroxidase enzymes, in MCF-7, HL-60, CCRF-CEM, UKF-NB-3, UKF-NB-4 and U87MG cells, but not in neuroblastoma UKF-NB-3 cells. Therefore, DNA adduct formation in most cancer cell lines tested in this comparative study might be the predominant cause of their sensitivity to ellipticine treatment, whereas other mechanisms of ellipticine action also contribute to its cytotoxicity to neuroblastoma UKF-NB-3 cells.

Keywords: DNA adducts; Ellipticine; cancer cell lines; mechanims of acticancer effects of ellipticine

References

  1. Toxicology. 2007 Jul 1;236(1-2):50-60 - PubMed
  2. Int J Cancer. 2010 Sep 1;127(5):1240-8 - PubMed
  3. Biochim Biophys Acta. 2011 Jan;1814(1):175-85 - PubMed
  4. Int J Cancer. 2003 Dec 20;107(6):885-90 - PubMed
  5. J Biol Chem. 1995 Jun 23;270(25):14998-5004 - PubMed
  6. Neuro Endocrinol Lett. 2009;30 Suppl 1:60-6 - PubMed
  7. Cancer Res. 2004 Nov 15;64(22):8374-80 - PubMed
  8. Arch Biochem Biophys. 1987 Nov 15;259(1):1-14 - PubMed
  9. Chem Res Toxicol. 2003 Jan;16(1):38-47 - PubMed
  10. Anticancer Drugs. 2005 Aug;16(7):789-95 - PubMed
  11. Cancer Lett. 2007 Jul 18;252(2):270-9 - PubMed
  12. Life Sci. 2006 Apr 25;78(22):2550-7 - PubMed
  13. Curr Med Chem Anticancer Agents. 2004 Mar;4(2):149-72 - PubMed
  14. Cancer Res. 1981 May;41(5):1690-4 - PubMed
  15. Anticancer Drugs. 1997 Nov;8(10):958-63 - PubMed
  16. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2006 Jul;150(1):13-23 - PubMed
  17. Cancer Lett. 2005 Jun 8;223(2):293-301 - PubMed
  18. Biochemistry. 1994 Aug 30;33(34):10271-85 - PubMed
  19. Biochem Pharmacol. 2001 Dec 15;62(12):1675-84 - PubMed
  20. Neuro Endocrinol Lett. 2008 Oct;29(5):728-32 - PubMed
  21. Anticancer Res. 1999 Jul-Aug;19(4B):3099-108 - PubMed
  22. Biochem Pharmacol. 2002 Jul 15;64(2):289-95 - PubMed
  23. Mol Pharmacol. 1992 Oct;42(4):590-5 - PubMed
  24. Jpn J Cancer Res. 1995 Sep;86(9):819-27 - PubMed
  25. Int J Cancer. 2007 Jan 15;120(2):243-51 - PubMed
  26. Biochem Pharmacol. 2009 May 1;77(9):1466-79 - PubMed
  27. J Biol Chem. 1991 Jan 25;266(3):1820-9 - PubMed
  28. Drug Metab Dispos. 2007 Oct;35(10):1926-34 - PubMed
  29. Toxicol Appl Pharmacol. 2008 Feb 1;226(3):318-27 - PubMed

Publication Types